KDR and glioblastoma: Despite its therapeutic potential in pre-clinical models of GBM, olaratumab showed minimal clinical efficacy in GBM patients, with a median overall survival (OS) of 34.3 weeks compared to the VEGFR inhibitor, ramucirumab (49.5 weeks) [25].